This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kasukawa, Y. Articles by Mohan, S. Search for Related Content PubMed PubMed Citation Articles by Kasukawa, Y. Articles by Mohan, S.

Evidence that Sensitivity to Growth Hormone (GH) Is Growth Period and Tissue Type Dependent: Studies in GH-Deficient lit/lit Mice

Musculoskeletal Disease Center (Y.K., D.J.B., R.G., S.M.), Jerry L. Pettis Veterans Affairs Medical Center, Loma Linda, California 92357; and Department of Medicine (D.J.B., S.M.), Biochemistry (S.M.), and Department of Physiology (S.M.), Loma Linda University, Loma Linda, California 92354

Address all correspondence and requests for reprints to: Subburaman Mohan, Ph.D., Musculoskeletal Disease Center (151), Jerry L. Pettis Veterans Administration Medical Center, 11201 Benton Street, Loma Linda, California 92357. E-mail: mohans{at}lom.med.va.gov.

We previously found that the magnitude of skeletal deficits caused by GH deficiency varied during different growth periods. To test the hypothesis that the sensitivity to GH is growth period dependent, we treated GH-deficient lit/lit mice with GH (4 mg/kg body weight·d) or vehicle during the prepubertal and pubertal (d 7–34), pubertal (d 23–34), postpubertal (d 42–55), and adult (d 204–217) periods and evaluated GH effects on the musculoskeletal system by dual energy x-ray absorptiometry (DEXA) and peripheral quantitative computed tomography. GH treatment during different periods significantly increased total body bone mineral content, bone mineral density (BMD), bone area, and lean body mass and decreased percentage of fat compared with vehicle; however, the magnitude of change varied markedly depending on the treatment period. For example, the increase in total body BMD was significantly (P < 0.01) greater when GH was administered between d 42–55 (15%) compared with pubertal (8%) or adult (7.7%) periods, whereas the net loss in percentage of body fat was greatest (-56%) when GH was administered between d 204 and 216 and least (-27%) when GH was administered between d 7 and 35. To determine whether GH-induced anabolic effects on the musculoskeletal system are maintained after GH withdrawal, we performed DEXA measurements 3–7 wk after stopping GH treatment. The increases in total body bone mineral content, BMD, and lean body mass, but not the decrease in body fat, were sustained after GH withdrawal. Our findings demonstrate that the sensitivity to GH in target tissues is growth period and tissue type dependent and that continuous GH treatment is necessary to maintain body fat loss but not BMD gain during a 3–7 wk follow-up.

This article has been cited by other articles:

				I. Ueki, S. L. Giesy, K. J. Harvatine, J. W. Kim, and Y. R. Boisclair The Acid-Labile Subunit Is Required for Full Effects of Exogenous Growth Hormone on Growth and Carbohydrate Metabolism Endocrinology, July 1, 2009; 150(7): 3145 - 3152. [Abstract] [Full Text] [PDF]

				K. E. Govoni, J. E. Wergedal, L. Florin, P. Angel, D. J. Baylink, and S. Mohan Conditional Deletion of Insulin-Like Growth Factor-I in Collagen Type 1{alpha}2-Expressing Cells Results in Postnatal Lethality and a Dramatic Reduction in Bone Accretion Endocrinology, December 1, 2007; 148(12): 5706 - 5715. [Abstract] [Full Text] [PDF]

				B. T. Velayudhan, K. E. Govoni, T. A. Hoagland, and S. A. Zinn Growth rate and changes of the somatotropic axis in beef cattle administered exogenous bovine somatotropin beginning at two hundred, two hundred fifty, and three hundred days of age J Anim Sci, November 1, 2007; 85(11): 2866 - 2872. [Abstract] [Full Text] [PDF]

				K. E. Govoni, S. K. Lee, Y.-S. Chung, R. R. Behringer, J. E. Wergedal, D. J. Baylink, and S. Mohan Disruption of insulin-like growth factor-I expression in type II{alpha}I collagen-expressing cells reduces bone length and width in mice Physiol Genomics, August 20, 2007; 30(3): 354 - 362. [Abstract] [Full Text] [PDF]

				X. Cheng, J. Maher, H. Lu, and C. D. Klaassen Endocrine Regulation of Gender-Divergent Mouse Organic Anion-Transporting Polypeptide (Oatp) Expression Mol. Pharmacol., October 1, 2006; 70(4): 1291 - 1297. [Abstract] [Full Text] [PDF]

				K. E. Govoni, S. K. Lee, R. B. Chadwick, H. Yu, Y. Kasukawa, D. J. Baylink, and S. Mohan Whole genome microarray analysis of growth hormone-induced gene expression in bone: T-box3, a novel transcription factor, regulates osteoblast proliferation Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E128 - E136. [Abstract] [Full Text] [PDF]

				D. Fintini, M. Alba, and R. Salvatori Influence of Estrogen Administration on the Growth Response to Growth Hormone (GH) in GH-Deficient Mice Experimental Biology and Medicine, November 1, 2005; 230(10): 715 - 720. [Abstract] [Full Text] [PDF]

				S. J. Warden, A. G. Robling, M. S. Sanders, M. M. Bliziotes, and C. H. Turner Inhibition of the Serotonin (5-Hydroxytryptamine) Transporter Reduces Bone Accrual during Growth Endocrinology, February 1, 2005; 146(2): 685 - 693. [Abstract] [Full Text] [PDF]

				D. Fleenor, J. Oden, P. A. Kelly, S. Mohan, S. Alliouachene, M. Pende, S. Wentz, J. Kerr, and M. Freemark Roles of the Lactogens and Somatogens in Perinatal and Postnatal Metabolism and Growth: Studies of a Novel Mouse Model Combining Lactogen Resistance and Growth Hormone Deficiency Endocrinology, January 1, 2005; 146(1): 103 - 112. [Abstract] [Full Text] [PDF]